Author: Pistone, Aureliano; Tant, Laure; Soyfoo, Muhammad S
Title: Clinical course of COVID-19 infection in inflammatory rheumatologic patients: a monocentric Belgian experience Cord-id: fhsz55qv Document date: 2020_11_5
ID: fhsz55qv
Snippet: OBJECTIVES: Little is known about the incidence and consequences of COVID-19 infection in patients with rheumatic diseases. To improve our knowledge in this field, we collected data from patients with inflammatory rheumatic diseases, who developed COVID-19 infection. PATIENTS AND METHODS: We performed a monocentric observational longitudinal study and collected retrospectively data from patients with inflammatory rheumatic diseases who developed a confirmed or suspected COVID-19 infection betwee
Document: OBJECTIVES: Little is known about the incidence and consequences of COVID-19 infection in patients with rheumatic diseases. To improve our knowledge in this field, we collected data from patients with inflammatory rheumatic diseases, who developed COVID-19 infection. PATIENTS AND METHODS: We performed a monocentric observational longitudinal study and collected retrospectively data from patients with inflammatory rheumatic diseases who developed a confirmed or suspected COVID-19 infection between 3rd March and 10th June 2020. RESULTS: A total of 23 patients developed COVID-19 infection. Seven patients needed hospitalization (female 57%, mean age 59 ± 9 years) and sixteen patients were followed as outpatients (female 80%, mean age 50 ± 14 years). All hospitalized patients had more than one comorbidity. At the time of infection, all patients were on immunosuppressive therapy consisting of either csDMARDs and/or biotherapy with and without corticosteroids. A minority received corticosteroids only. The most common symptoms of COVID-19 infected patients were fever, dyspnoea, cough, and fatigue. Polymerase Chain Reaction (PCR) and chest computed tomography (CT) were performed in all hospitalized patients to confirm the diagnosis (100% positive PCR, 71% positive CT). All outclinic patients were clinically diagnosed (confirmed by PCR in only one). The mean length of hospital stay was 21 ± 19 days. Three patients developed an Acute Respiratory Distress Syndrome including one who died. CONCLUSIONS: A limited number of patients with inflammatory rheumatic diseases suffered from COVID-19 infection. Two patients needed mechanical ventilation and survived, while one patient died. All patients with severe form of infection had at least one comorbidity.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and longitudinal study: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and low incidence: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7
- longitudinal study and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9
- longitudinal study and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- longitudinal study and lung epithelial cell: 1
- longitudinal study and lupus erythematosus: 1, 2, 3, 4
- lopinavir receive and lung disease: 1
- low incidence and lung disease: 1, 2, 3, 4
- low incidence and lupus erythematosus: 1
- lung disease and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- lung disease and lymphocyte activation: 1, 2
- lupus erythematosus and lymphocyte activation: 1
Co phrase search for related documents, hyperlinks ordered by date